Second malignancies in early stage laryngeal carcinoma patients treated with radiotherapy

John Holland, Amir Arsanjani, Benny J. Liem, S. Christopher Hoffelt, James Cohen, Kenneth Stevens

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

A retrospective review of 240 patients with T1/T2 squamous cell carcinomas of the larynx was performed. Seventy-two per cent had glottic primaries, 27 per cent had supraglottic tumours and one per cent had subglottic disease. Sixty-nine per cent presented with T1 disease and 31 per cent had T2 staged tumours. All patients were treated with definitive radiotherapy between 1973 and 1997. With a median follow-up of 68 months, 68 patients (28 per cent) have developed 72 other cancers. Ten of 68 presented with synchronous primaries (15 per cent). Thirty per cent of glottic patients and 25 per cent of the supraglottic/subglottic patients developed second cancers. The most frequent second malignancy was lung cancer: 28/72 (39 per cent). Fifteen patients developed second head and neck cancers (21 per cent). Other second primary sites included oesophagus (eight), prostate (six), colorectal (five), breast (two) and others (eight). The median time from radiotherapy until the development of a second cancer was 31 months. The Kaplan-Meier survival estimate at five years was significantly less for those patients developing second cancers (55 per cent) compared to those not developing second malignancies (70 per cent), (p

Original languageEnglish (US)
Pages (from-to)190-193
Number of pages4
JournalJournal of Laryngology and Otology
Volume116
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Second Primary Neoplasms
Radiotherapy
Carcinoma
Tongue
Neoplasms
Kaplan-Meier Estimate
Head and Neck Neoplasms
Larynx
Esophagus
Prostate
Squamous Cell Carcinoma
Lung Neoplasms
Breast
Survival

Keywords

  • Carcinoma
  • Larynx
  • Local
  • Neoplasm Recurrence
  • Neoplasms
  • Radiotherapy
  • Second Primary
  • Squamous Cell

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Second malignancies in early stage laryngeal carcinoma patients treated with radiotherapy. / Holland, John; Arsanjani, Amir; Liem, Benny J.; Christopher Hoffelt, S.; Cohen, James; Stevens, Kenneth.

In: Journal of Laryngology and Otology, Vol. 116, No. 3, 2002, p. 190-193.

Research output: Contribution to journalArticle

Holland, John ; Arsanjani, Amir ; Liem, Benny J. ; Christopher Hoffelt, S. ; Cohen, James ; Stevens, Kenneth. / Second malignancies in early stage laryngeal carcinoma patients treated with radiotherapy. In: Journal of Laryngology and Otology. 2002 ; Vol. 116, No. 3. pp. 190-193.
@article{09d93d329da1463489370672bf6a4f8b,
title = "Second malignancies in early stage laryngeal carcinoma patients treated with radiotherapy",
abstract = "A retrospective review of 240 patients with T1/T2 squamous cell carcinomas of the larynx was performed. Seventy-two per cent had glottic primaries, 27 per cent had supraglottic tumours and one per cent had subglottic disease. Sixty-nine per cent presented with T1 disease and 31 per cent had T2 staged tumours. All patients were treated with definitive radiotherapy between 1973 and 1997. With a median follow-up of 68 months, 68 patients (28 per cent) have developed 72 other cancers. Ten of 68 presented with synchronous primaries (15 per cent). Thirty per cent of glottic patients and 25 per cent of the supraglottic/subglottic patients developed second cancers. The most frequent second malignancy was lung cancer: 28/72 (39 per cent). Fifteen patients developed second head and neck cancers (21 per cent). Other second primary sites included oesophagus (eight), prostate (six), colorectal (five), breast (two) and others (eight). The median time from radiotherapy until the development of a second cancer was 31 months. The Kaplan-Meier survival estimate at five years was significantly less for those patients developing second cancers (55 per cent) compared to those not developing second malignancies (70 per cent), (p",
keywords = "Carcinoma, Larynx, Local, Neoplasm Recurrence, Neoplasms, Radiotherapy, Second Primary, Squamous Cell",
author = "John Holland and Amir Arsanjani and Liem, {Benny J.} and {Christopher Hoffelt}, S. and James Cohen and Kenneth Stevens",
year = "2002",
doi = "10.1258/0022215021910500",
language = "English (US)",
volume = "116",
pages = "190--193",
journal = "Journal of Laryngology and Otology",
issn = "0022-2151",
publisher = "Cambridge University Press",
number = "3",

}

TY - JOUR

T1 - Second malignancies in early stage laryngeal carcinoma patients treated with radiotherapy

AU - Holland, John

AU - Arsanjani, Amir

AU - Liem, Benny J.

AU - Christopher Hoffelt, S.

AU - Cohen, James

AU - Stevens, Kenneth

PY - 2002

Y1 - 2002

N2 - A retrospective review of 240 patients with T1/T2 squamous cell carcinomas of the larynx was performed. Seventy-two per cent had glottic primaries, 27 per cent had supraglottic tumours and one per cent had subglottic disease. Sixty-nine per cent presented with T1 disease and 31 per cent had T2 staged tumours. All patients were treated with definitive radiotherapy between 1973 and 1997. With a median follow-up of 68 months, 68 patients (28 per cent) have developed 72 other cancers. Ten of 68 presented with synchronous primaries (15 per cent). Thirty per cent of glottic patients and 25 per cent of the supraglottic/subglottic patients developed second cancers. The most frequent second malignancy was lung cancer: 28/72 (39 per cent). Fifteen patients developed second head and neck cancers (21 per cent). Other second primary sites included oesophagus (eight), prostate (six), colorectal (five), breast (two) and others (eight). The median time from radiotherapy until the development of a second cancer was 31 months. The Kaplan-Meier survival estimate at five years was significantly less for those patients developing second cancers (55 per cent) compared to those not developing second malignancies (70 per cent), (p

AB - A retrospective review of 240 patients with T1/T2 squamous cell carcinomas of the larynx was performed. Seventy-two per cent had glottic primaries, 27 per cent had supraglottic tumours and one per cent had subglottic disease. Sixty-nine per cent presented with T1 disease and 31 per cent had T2 staged tumours. All patients were treated with definitive radiotherapy between 1973 and 1997. With a median follow-up of 68 months, 68 patients (28 per cent) have developed 72 other cancers. Ten of 68 presented with synchronous primaries (15 per cent). Thirty per cent of glottic patients and 25 per cent of the supraglottic/subglottic patients developed second cancers. The most frequent second malignancy was lung cancer: 28/72 (39 per cent). Fifteen patients developed second head and neck cancers (21 per cent). Other second primary sites included oesophagus (eight), prostate (six), colorectal (five), breast (two) and others (eight). The median time from radiotherapy until the development of a second cancer was 31 months. The Kaplan-Meier survival estimate at five years was significantly less for those patients developing second cancers (55 per cent) compared to those not developing second malignancies (70 per cent), (p

KW - Carcinoma

KW - Larynx

KW - Local

KW - Neoplasm Recurrence

KW - Neoplasms

KW - Radiotherapy

KW - Second Primary

KW - Squamous Cell

UR - http://www.scopus.com/inward/record.url?scp=0036189063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036189063&partnerID=8YFLogxK

U2 - 10.1258/0022215021910500

DO - 10.1258/0022215021910500

M3 - Article

C2 - 11893260

AN - SCOPUS:0036189063

VL - 116

SP - 190

EP - 193

JO - Journal of Laryngology and Otology

JF - Journal of Laryngology and Otology

SN - 0022-2151

IS - 3

ER -